Searched for
PIRAMAL Q4
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsFrom a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...
- Q4 earnings roundup: Raymond Realty, MCX among 19 companies that delivered 100%+ growth in sales and PATA select group of 19 large-cap BSE-listed companies achieved triple-digit growth in both profit and revenue during Q4FY26, indicating stron...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Vedanta demerger: When will the four new stocks list on NSE, BSE? Here's what investors can expectVedanta’s demerger has left investors awaiting the listing of its four newly carved-out entities, even as the parent stock continues to ris...
- Piramal Pharma shares in focus after US FDA issues six observations for Mumbai facilityPiramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, resulting in a F...
- Piramal Pharma shares soar 11%, hit 52-week high after Q4 profit jumps 102% YoYThe company's revenue from operations increased by 18% to Rs 2,552.4 crore as against Rs 2,163.6 crore in the corresponding period of the p...
- Piramal Pharma Q4 Results: Net profit slides 75% YoY to Rs 50 croreOn like-to-like financials, the CDMO business that contributes 57% of revenues, declined 8% YoY to Rs 2164 crore. The complex hospital gene...
- Piramal Pharma shares jump over 10%. Here's whyPiramal Pharma's shares rose 10.2% on BSE after the US FDA concluded its inspection at the company’s Sellersville manufacturing facility. T...
- Piramal Enterprises Q4 Results: Firm posts profit of Rs 151 cr vs loss of Rs 510 croreFor the whole financial year 2021-22, it reported a 41 per cent jump in the net profit at around Rs 2,000 crore, it said in a release. Duri...
- Piramal Enterprises Q4 results: Net loss narrows to Rs 510 croreRevenue from operations stood at Rs 3,401.56 crore in the quarter under review. It was Rs 3,341 crore in the year-ago period, it added.
- Piramal Enterprises Q4 profit dives 88% to Rs 456 croreConsolidated revenue from operations stood at Rs 3,679.67 crore.
- Piramal Q4 net up 21% at Rs 375 croreThe company had reported a net profit of Rs 311 crore during the same period of the previous fiscal.
- Piramal Enterprises total operating income up by 62% to Rs 864 croresTotal operating income for the quarter grew by 61.5% from Rs 534.7 crores in Q2FY2012 to Rs 863.5 crores in Q2FY2013.
- Piramal Life Sciences Q4 net loss at Rs 40.97 crPiramal Life Sciences today said its net loss widened to Rs 40.97 crore in the fourth quarter ended March 31, 2011.
- Piramal Glass Q4 net surges three-fold to Rs 32.71 crPiramal Glass today said its consolidated net profit surged nearly three-fold to Rs 32.71 crore for the fourth quarter ended March 31, 2011.
- Piramal Glass nets Rs 12 crConsolidated sales rose 8.4% to Rs 283.6 crore from Rs 261.7 crore.
Load More
